Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan medoxomil 40 mg + amlodipine 5 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Olmetyle A 40 Tablet is a fixed-dose combination of Olmesartan Medoxomil (40 mg), an angiotensin II receptor blocker (ARB), and Amlodipine (5 mg), a calcium channel blocker. Together, these two antihypertensive agents act synergistically to lower elevated blood pressure. Olmesartan blocks the action of angiotensin II, thereby relaxing blood vessels, while Amlodipine prevents calcium influx in vascular smooth muscles, resulting in vasodilation. This dual mechanism helps in effective and sustained blood pressure control, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and kidney complications.
Olmetyle A 40 Tablet is usually well tolerated. Common side effects may include dizziness, headache, flushing, peripheral edema, and fatigue. In rare cases, hypotension, bradycardia, or allergic reactions may occur. Medical supervision is advised if any severe symptoms or persistent side effects are experienced.
This combination is indicated for the treatment of hypertension, especially in patients whose blood pressure is not adequately controlled on monotherapy. It may be particularly useful in individuals requiring multiple antihypertensive mechanisms for optimal BP management.
This medicine should only be taken under medical supervision. It is contraindicated in pregnancy, especially after the first trimester, due to the risk of fetal toxicity. Caution is advised in patients with severe liver or kidney impairment. Avoid abrupt discontinuation and do not exceed the recommended dose.
Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Composition : Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan Medoxomil 20 mg tablet
Composition : Nicorandil 10 mg Tablet
Composition : Nicorandil (5mg) Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil 40 mg + Amlodipine 5 mg Tablet is a high-strength combination antihypertensive medication used for the management of moderate to severe hypertension (high blood pressure). It combines Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), with Amlodipine, a calcium channel blocker that relaxes blood vessels and improves blood circulation. This dual-action therapy ensures effective and long-lasting blood pressure control, making it highly valuable in the cardiology and cardiovascular care segment with strong demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. Due to the high prevalence of hypertension and the preference for combination therapies, this product ensures regular prescriptions, repeat orders, and long-term market stability, making it a strong portfolio addition.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality-assured manufacturing, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription demand, long-term patient adherence, increasing cardiovascular healthcare needs, and continuous institutional requirements, making this product a profitable and sustainable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.